During Friday’s Current trade, Shares of Arista Netoperates Inc (NYSE:ANET), gain 0.83% to $65.27.
Arista Netoperates (ANET) declared a new portfolio of data center switches that address the demand for 25/50/100GbE switching. Arista EOS (extensible operating system) features such as Smart System Upgrade with hitless software upgrades, hitless speed change and network rollback, provide customers with non-stop operational tools for building cloud scale netoperates.
The new family of Arista 7060X, 7260X and 7320X fixed-leaf and modular-spline form factors gives customers choices for building scalable 100GbE netoperates with comprehensive support for both 25GbE and 50GbE in addition to for seamless migration from existing 10G and 40G netoperates. Broad support for workflow automation and workload orchestration is offered through the CloudVision suite, ensuring operational compriseency across all Arista platforms.
Arista Netoperates, Inc. provides cloud networking solutions. The company offers extensible operating systems, a set of network applications, and Ethernet switches. It serves a range of industries, counting Internet companies, service providers, financial services organizations, government agencies, media and entertainment companies, and others.
Shares of UTi Worldwide Inc. (NASDAQ:UTIW), declined -1.50% to $5.93, during its current trading session.
UTi Worldwide Inc. (UTIW), a global supply chain services and solutions provider, has promoted two executives to better align the company’s capabilities and expertise with the evolving needs of its freight forwarding clients.
UTi designated Jerry Trimarco to Global Vice President, Sales — Freight Forwarding. A 40-year veteran of the freight forwarding industry, he joined UTi in 2010 as Vice President, Global Air Product. Formerly, he held senior leadership roles in sales, global transportation, airline administration and field operations with UPS Supply Chain Solutions, Emery Worldwide and Menlo Worldwide.
UTi also designated John Wetherell to Vice President, Global Air Product. A 22-year veteran of the freight forwarding industry, he stated to Trimarco and led UTi’s Air Product and Procurement team in the Americas region. In his new role, he is responsible for the planned development and administration of UTi’s air forwarding business and products globally. He joined UTi in 2006 from Exel, where he began his supply chain career at MSAS, holding senior administration positions in both operations and product administration.
UTi Worldwide Inc. operates as a non-asset-based supply chain services and solutions company. It operates through two segments, Freight Forwarding, and Contract Logistics and Distribution.
Parker-Hannifin Corp (NYSE:PH), during its Friday’s current trading session decreased -2.94% to $103.54.
Hannifin Corporation (PH), the global leader in motion and control technologies, declared that it will webcast an investor meeting from the Pierre Hotel in New York City on Tuesday, September 22, 2015 starting at 1:00 p.m. Eastern time until about 4:00 p.m. Eastern time. A series of formal presentations focused on Parker`s strategies for long-term profitable growth will be followed by a question and answer period hosted by Parker`s executive leadership.
Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for various mobile, industrial, and aerospace markets worldwide. The company operates in two segments, Diversified Industrial and Aerospace Systems.
Finally, Inovio Pharmaceuticals Inc (NASDAQ:INO), decreased -3.01%, to $7.41.
Inovio Pharmaceuticals, Inc. (INO) declared that The Lancet, one of the world’s leading medical journals, published a peer-reviewed article detailing the successful results of its phase 2b trial with VGX-3100 in treating women with high grade cervical neoplasia. Formerly, medical researchers have tried to stimulate therapeutic immune responses against the human papillomavirus (HPV) and cervical lesions with little success. This publication details that VGX-3100, a first-in-class product for treating high grade cervical neoplasia associated with HPV, is the first therapy to demonstrate that activated killer T cells induced in the body have the power to clear neoplastic lesions in addition to the virus which caused the disease.
Commenting on Inovio’s HPV results, two senior investigators at the U.S. National Cancer Institute Division of Cancer Epidemiology & Genetics (Dr. Mark Schiffman and Dr. Nicolas Wentzensen) wrote in The Lancet: “The current trial represents a major breakthrough and proof-of-principle that therapeutic HPV vaccination is feasible. More broadly, the trial shows that it is possible to boost immune clearance of HPV among women who initially failed to control infection.”
Specifically, the phase 2b trial showed that histopathological regression of high grade cervical neoplasia (CIN2/3) to low grade neoplasia (CIN 1) or no disease occurred in a significantly higher percentage of VGX-3100 recipients contrast with placebo recipients. Furthermore, concomitant histopathological regression and clearance of HPV occurred in a significantly higher percentage of VGX-3100 recipients contrast with placebo recipients. HPV-specific CD8+ “killer T cells” were also generated in the blood in addition to a substantial infiltration of CD8+ cells in the cervical tissue of VGX-3100 recipients, underscoring the role played by Inovio’s best-in-class T-cell responses. VGX-3100 was safe and generally well-tolerated.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
